InspireMD (NSPR) Shares are Down -20.58%

InspireMD (NSPR) : During the past 4 weeks, traders have been relatively bearish on InspireMD (NSPR), hence the stock is down -9.82% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -20.62% relative to the S&P 500. The 4-week change in the price of the stock is -8.89% and the stock has fallen -20.58% in the past 1 week.

The stock has recorded a 20-day Moving Average of 13.85% and the 50-Day Moving Average is 42%. InspireMD (NYSEMKT:NSPR): stock turned positive on Friday. Though the stock opened at $0.1628, the bulls momentum made the stock top out at $0.1639 level for the day. The stock recorded a low of $0.1521 and closed the trading day at $0.1598, in the green by 3.03%. The total traded volume for the day was 940,488. The stock had closed at $0.1551 in the previous days trading.


The company Insiders own 24.28% of InspireMD shares according to the proxy statements. Institutional Investors own 9.33% of InspireMD shares. During last six month period, the net percent change held by insiders has seen a change of 303.47%.

InspireMD, Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Companys MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Companys MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Companys second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *